EMPOWER CAD isthe First Prospective, Female-Only Study of Coronary Interventions
StudySeeks to Confirm Benefits of Shockwave's Coronary IVL in FemalesWho Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies
SANTA CLARA, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has initiated the first-ever prospective coronary intervention study consisting of all female patients – EMPOWER CAD – to determine whether the positive results from earlier coronary IVL studies with the Shockwave C2 Coronary IVL Catheter, which showed similar...